Prognostic significance of BRCA mutations in ovarian cancer: an updated systematic review with meta-analysis.
There is no consensus on the syntheses concerning the impact of BRCA mutation on ovarian cancer survival. A systematic review and meta-analysis of observational studies was conducted that evaluated the impact of BRCA mutations on the survival outcomes of patients with ovarian cancer. The primary outcome measure was overall survival (OS) and secondary outcome was progression-free survival (PFS). We presented data with hazard ratios (HRs) and 95% confidence interval (CI) and pooled them using the random-effects models. From 2,624 unique records, 34 eligible studies including 18,396 patients were identified. BRCA1/2 mutations demonstrated both OS and PFS benefits in patients with ovarian cancer (OS: HR = 0.67, 95% CI, 0.57 to 0.78, I2 = 76.5%, P <0.001; PFS: HR = 0.62, 95% CI, 0.53 to 0.73, I2 = 18.1%, P = 0.261). For BRCA1 mutation carriers, the HRs for OS and PFS benefits were 0.73 (95% CI, 0.63 to 0.86) and 0.68 (95% CI, 0.52 to 0.89), respectively. For BRCA2 mutation carriers, the HRs for OS and PFS benefits were 0.57 (95% CI, 0.45 to 0.73) and 0.48 (95% CI, 0.30 to 0.75), respectively. The results of subgroup analyses for OS stratified by study quality, tumor stage, study design, sample size, number of research center, duration of follow-up, baseline characteristics adjusted and tumor histology were mostly constant across BRCA1/2, BRCA1 and BRCA2 mutation subtypes. In summary, for patients with ovarian cancer, BRCA mutations were associated with improved OS and PFS. Further large-scale prospective cohort studies should be conducted to test its benefits in specific patients.
Department of Otolaryngology-Head and Neck Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province, China.
Kai
K
Xu
Department of Obstetrics and Gynecology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province, China.
Shouhua
S
Yang
Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province, China.
Yingchao
Y
Zhao
D019313:BRCA1 Protein / Q000235:genetics*; D024682:BRCA2 Protein / Q000235:genetics*; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D009154:Mutation; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000235:genetics* / Q000401:mortality* / Q000473:pathology; D011379:Prognosis; D016019:Survival Analysis; D047368:Tumor Burden
D019313:BRCA1 Protein; C492913:BRCA1 protein, human; D024682:BRCA2 Protein; C551750:BRCA2 protein, human
BRCA mutation; meta-analysis; ovarian cancer; prognosis; systematic review
J Clin Oncol. 2012 Jul 20;30(21):2654-63
22711857
Fam Cancer. 2016 Oct;15(4):497-506
26833043
J Natl Cancer Inst. 2013 Jun 5;105(11):812-22
23628597
DNA Repair (Amst). 2014 Jul;19:169-75
24746645
J Clin Oncol. 2008 Dec 1;26(34):5530-6
18955455
J Clin Oncol. 2008 Jan 1;26(1):20-5
18165636
Biometrics. 1994 Dec;50(4):1088-101
7786990
Clin Cancer Res. 2015 Feb 1;21(3):652-7
25398451
Clin Cancer Res. 2015 Jan 1;21(1):211-20
25348513
J Clin Oncol. 2002 Jan 15;20(2):463-6
11786575
Exp Cell Res. 2014 Nov 15;329(1):18-25
25017100
JAMA. 2000 May 3;283(17):2260-5
10807385
Gynecol Oncol. 2016 Mar;140(3):443-9
26740259
PLoS One. 2014 Dec 01;9(12):e113169
25437005
Control Clin Trials. 1986 Sep;7(3):177-88
3802833
Gynecol Oncol. 2011 May 1;121(2):358-63
21276604
J Clin Oncol. 2010 Aug 1;28(22):3570-6
20606085
Clin Cancer Res. 2002 May;8(5):1196-202
12006538
Int J Gynecol Cancer. 2014 Oct;24(8):1395-400
25248112
Biometrics. 2000 Jun;56(2):455-63
10877304
Cancer. 2012 Aug 1;118(15):3703-9
22139894
Eur J Cancer. 2005 Jan;41(1):143-50
15617999
BMJ. 2003 Sep 6;327(7414):557-60
12958120
Eur J Surg Oncol. 2001 Apr;27(3):278-81
11373105
Eur J Obstet Gynecol Reprod Biol. 2001 Oct;98(2):219-23
11574135
N Engl J Med. 1996 Nov 7;335(19):1413-6
8875917
Sci Rep. 2014 Feb 07;4:4026
24504028
J Natl Cancer Inst. 2013 Jan 16;105(2):141-8
23257159
JAMA. 2011 Oct 12;306(14):1557-65
21990299
Clin Cancer Res. 2014 Feb 1;20(3):764-75
24240112
J Natl Cancer Inst. 2014 Jun;106(6):dju091
24824314
Cancer. 2003 May 1;97(9):2187-95
12712470
Cancer Res. 2015 Aug 1;75(15):2987-98
26122843
Ann Oncol. 2011 May;22(5):1127-32
21084428
Gynecol Oncol. 2012 Jun;125(3):677-82
22406760
Biomed Res Int. 2014;2014:787143
25136623
Clin Cancer Res. 1998 Jan;4(1):235-40
9516977
Cancer Res. 1999 Feb 15;59(4):868-71
10029077
Gynecol Oncol. 2016 Jan;140(1):42-7
26556769
BMJ. 1997 Sep 13;315(7109):629-34
9310563
PLoS One. 2014 May 01;9(5):e95285
24788697
J Clin Oncol. 1998 Feb;16(2):397-404
9469321
Fam Cancer. 2007;6(1):113-9
17160431
Ann Oncol. 2013 Nov;24 Suppl 8:viii63-viii68
24131973
Hered Cancer Clin Pract. 2016 Jan 08;14:1
26753012
Nat Rev Cancer. 2011 Dec 23;12(1):68-78
22193408